Moderna/$MRNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Ticker
- $MRNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,700
- Headquarters
- Cambridge, United States
- Website
- www.modernatx.com
Moderna Metrics
BasicAdvanced
$78B
-
-$8.01
1.11
-
Price and volume
Market cap
$78B
Beta
1.11
52-week high
$212.22
52-week low
$22.28
Average daily volume
16M
Financial strength
Current ratio
2.295
Quick ratio
2.068
Long term debt to equity
0.183
Total debt to equity
0.183
Interest coverage (TTM)
-58.00%
Profitability
EBITDA (TTM)
-2,195
Gross margin (TTM)
-66.02%
Net profit margin (TTM)
-141.43%
Operating margin (TTM)
-109.34%
Effective tax rate (TTM)
-2.07%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-13.26%
Return on equity (TTM)
-39.00%
Valuation
Price to revenue (TTM)
34.701
Price to book
11.6
Price to tangible book (TTM)
11.88
Price to free cash flow (TTM)
-62.15
Free cash flow yield (TTM)
-1.61%
Free cash flow per share (TTM)
-3.161
Growth
Revenue change (TTM)
-27.62%
Earnings per share change (TTM)
6.47%
3-year revenue growth (CAGR)
-40.64%
3-year earnings per share growth (CAGR)
37.86%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Analyst projections of the future price of Moderna stock.
Bulls say / Bears say
Moderna and Merck’s personalised cancer vaccine produced positive Phase 3 melanoma results in more than 1,000 patients, extending recurrence-free survival and reducing the risk of distant spread when added to Keytruda. The result validates Moderna’s mRNA approach outside infectious disease and supports ongoing late-stage trials in lung, bladder and kidney cancers. (Reuters, CNBC)
The FDA approved mFLUSIVA for adults aged 50 and over, making it the first approved mRNA flu vaccine in the United States. Its Phase 3 study showed 26.6% relative efficacy versus a standard-dose flu vaccine, giving Moderna a sizeable new respiratory market and further proof that its platform can produce products beyond COVID-19. (Moderna, Moderna)
Moderna is building a broader international commercial base: the European Commission agreed to procure up to 24 million mRESVIA doses for six countries, while the company added approvals and supply partnerships across several markets. Management kept its target of up to 10% 2026 revenue growth and improved its projected year-end cash range, suggesting diversification and cost control are beginning to offset weaker US COVID demand. (Newswire)
Moderna remains deeply loss-making: second-quarter revenue was $145 million against a $782 million net loss. Cash fell to $6.9 billion by June, and the company paid a further $950 million litigation settlement in July, leaving its costly transition dependent on continued spending cuts. (Newswire)
Although mFLUSIVA has been approved, its use in people aged 65 and over relies on accelerated approval based on immune responses and requires confirmatory evidence of clinical benefit. The absence of a settled ACIP recommendation also creates uncertainty over doctors’ guidance, reimbursement and the speed of the launch. (FDA, Ars Technica)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Upcoming events
No upcoming events
Moderna News
AllArticlesVideos
Funds containing Moderna
AllUSDGBPEUR
Fund name | Fund size | $MRNA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 5.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 5.08% |
iShares Healthcare Innovation$HEAL | $1.4B | 4.86% |
iShares Healthcare Innovation€2B78 | €1.2B | 4.86% |
iShares Healthcare Innovation£DRDR | £1B | 4.86% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.